Human lung tissue provides highly relevant data about efficacy of new anti-asthmatic drugs

2018 | journal article

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Human lung tissue provides highly relevant data about efficacy of new anti-asthmatic drugs​
Danov, O.; Jiménez Delgado, S. M.; Obernolte, H.; Seehase, S.; Dehmel, S.; Braubach, P. & Fieguth, H.-G. et al.​ (2018) 
PlOS ONE13(11) art. e0207767​.​ DOI: https://doi.org/10.1371/journal.pone.0207767 

Documents & Media

journal.pone.0207767.pdf1.61 MBAdobe PDF

License

Published Version

Attribution 4.0 CC BY 4.0

Details

Authors
Danov, Olga; Jiménez Delgado, Sharon Melissa; Obernolte, Helena; Seehase, Sophie; Dehmel, Susann; Braubach, Peter; Fieguth, Hans-Gerd; Matschiner, Gabriele; Fitzgerald, Mary; Jonigk, Danny; Knauf, Sascha; Pfennig, Olaf; Warnecke, Gregor; Wichmann, Judy; Braun, Armin; Sewald, Katherina
Abstract
Subgroups of patients with severe asthma are insensitive to inhaled corticosteroids and require novel therapies on top of standard medical care. IL-13 is considered one of the key cytokines in the asthma pathogenesis, however, the effect of IL-13 was mostly studied in rodents. This study aimed to assess IL-13 effect in human lung tissue for the development of targeted therapy approaches such as inhibition of soluble IL-13 or its receptor IL-4Rα subunit. Precision-cut lung slices (PCLS) were prepared from lungs of rodents, non-human primates (NHP) and humans. Direct effect of IL-13 on human lung tissue was observed on inflammation, induction of mucin5AC, and airway constriction induced by methacholine and visualized by videomicroscopy. Anti-inflammatory treatment was evaluated by co-incubation of IL-13 with increasing concentrations of IL-13/IL-13 receptor inhibitors. IL-13 induced a two-fold increase in mucin5AC secretion in human bronchial tissue. Additionally, IL-13 induced release of proinflammatory cytokines eotaxin-3 and TARC in human PCLS. Anti-inflammatory treatment with four different inhibitors acting either on the IL-13 ligand itself (anti-IL-13 antibody, similar to Lebrikizumab) or the IL-4Rα chain of the IL-13/IL-4 receptor complex (anti-IL-4Rα #1, similar to AMG 317, and #2, similar to REGN668) and #3 PRS-060 (a novel anticalin directed against this receptor) could significantly attenuate IL-13 induced inflammation. Contrary to this, IL-13 did not induce airway hyperresponsiveness (AHR) in human and NHP PCLS, although it was effective in rodent PCLS. Overall, this study demonstrates that IL-13 stimulation induces production of mucus and biomarkers of allergic inflammation in human lung tissue ex-vivo but no airway hyperresponsiveness. The results of this study show a more distinct efficacy than known from animals models and a clear discrepancy in AHR induction. Moreover, it allows a translational approach in inhibitor profiling in human lung tissue.
Issue Date
2018
Journal
PlOS ONE 
Organization
Deutsches Primatenzentrum 
ISSN
1932-6203
Language
English

Reference

Citations


Social Media